title: Amelioration of intestinal colitis by macrophage migration inhibitory factor isolated from intestinal parasites through toll-like receptor 2.
abstract: In a previous study, we cloned type II MIFs (As-MIF) from Anisakis simplex 3rd stage larva and expressed a recombinant protein that suppressed allergic airway inflammation via regulatory T (CD4(+) CD25(+) Foxp3(+) T; T(reg) )-cell recruitment. In this study, in an effort to evaluate the function of rAs-MIF on another immune disease, we induced intestinal inflammation in mice using dextran sodium sulphate (DSS) with or without the application of rAs-MIF treatment to the mice. As a consequence, weight losses were recovered, and the value of disease activity index (DAI) was reduced by rAs-MIF treatment during the experimental period. The levels of TGF-β and IL-10 in the spleens and mesenteric lymph nodes (MLN) from the rAs-MIF-treated mice were higher, but the levels of IFN-γ, IL-6 and IL-13 were lower than those of the mice treated with DSS but not with rAs-MIF. Additionally, the T(reg) cells observed were greatly increased in the MLNs of the rAs-MIF-treated mice than those of mice not treated with rAs-MIF. The results of our in vitro experiments showed that the elevated IL-10 production induced by rAs-MIF was generated via toll-like receptor 2. In conclusion, rAs-MIF appears to ameliorate DSS-induced colitis and may prove useful as a therapeutic agent for the treatment of intestinal inflammatory disease.
authors.affiliation: Department of Parasitology, School of Medicine, Pusan National University, Yangsan, Korea.
authors.forename: M K
authors.initials: MK
authors.lastname: Cho
authors.forename: C H
authors.initials: CH
authors.lastname: Lee
authors.forename: H S
authors.initials: HS
authors.lastname: Yu
mesh_terms: D000818:Animals; D017163:Anisakis / Q000737:chemistry*; D001835:Body Weight; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy*; D016207:Cytokines / Q000032:analysis; D016264:Dextran Sulfate / Q000008:administration & dosage / Q000633:toxicity; D005260:Female; D015801:Helminth Proteins / Q000008:administration & dosage* / Q000302:isolation & purification; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000302:isolation & purification; D008263:Macrophage Migration-Inhibitory Factors / Q000008:administration & dosage* / Q000302:isolation & purification; D051379:Mice; D008810:Mice, Inbred C57BL; D012720:Severity of Illness Index; D013154:Spleen / Q000276:immunology; D051195:Toll-Like Receptor 2 / Q000276:immunology* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D016207:Cytokines; D015801:Helminth Proteins; D007155:Immunologic Factors; D008263:Macrophage Migration-Inhibitory Factors; C493486:Tlr2 protein, mouse; D051195:Toll-Like Receptor 2; D016264:Dextran Sulfate